Rocket Pharmaceuticals公司宣布，其候选药物Rp-A501在首批三名患者中表现出良好的耐受性。值得关注的是，在这项初步研究中，没有观察到血栓性微血管病（TMA）或毛细血管渗漏综合征的发生。这一结果标志着该药物在安全性方面迈出了积极的一步，为后续临床开发提供了有力支撑。
Rocket Pharmaceuticals公司宣布，其候选药物Rp-A501在首批三名患者中表现出良好的耐受性。值得关注的是，在这项初步研究中，没有观察到血栓性微血管病（TMA）或毛细血管渗漏综合征的发生。这一结果标志着该药物在安全性方面迈出了积极的一步，为后续临床开发提供了有力支撑。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.